Q: What is Idhifa used for?

Idhifa is used to treat acute myeloid leukemia with IDH2 mutation .

Q: How does Idhifa work?

Targeting the IDH2 Mutation Idhifa is designed for people with acute myeloid leukemia (AML) who have a specific genetic mutation in the isocitrate dehydrogenase-2 (IDH2) enzyme. In a healthy body, this enzyme helps cells produce energy. However, when the enzyme is mutated, it causes the body to produce too much of a substance called 2-hydroxyglutarate (2-HG). Restoring Cell Maturity High levels of 2-HG interfere with the normal development of blood cells. Instead of maturing into functional white blood cells that fight infection, the cells remain in an immature state known as blasts. These blasts multiply quickly and crowd out healthy blood cells in the bone marrow and blood. Idhifa works by: Blocking the mutated enzyme: The medication attaches to the mutated IDH2 enzyme to stop it from working. Reducing 2-HG levels: By blocking the enzyme, Idhifa lowers the amount of 2-HG in the body. Promoting differentiation: Once 2-HG levels drop, the immature leukemia cells are able to go through a process called differentiation, where they mature into normal, working blood cells. Because Idhifa helps cells mature rather than simply killing them immediately, it is considered a type of differentiation therapy.

Q: What are the active ingredients in Idhifa?

The active ingredient in Idhifa is enasidenib .

Q: What are the side effects of Idhifa?

Common side effects of Idhifa may include: Nausea Diarrhea Fatigue and others. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Idhifa?

Idhifa belongs to the IDH2 inhibitor drug class.

Q: What is the dosage of Idhifa and how do I take it?

How to Take Idhifa Idhifa comes as a tablet to be taken by mouth. It is usually taken once a day at approximately the same time. You may take this medication with or without food. When taking Idhifa, follow these instructions: Swallow the tablet whole. Do not crush, chew, or break the tablet before swallowing. Missed Doses If you miss a dose of Idhifa, or if you vomit after taking a dose, take the missed dose as soon as you remember on the same day. If it is already the next day, skip the missed dose and take your next scheduled dose at the regular time. Do not take two doses at the same time to make up for a missed or vomited dose.

Q: Is Idhifa safe during pregnancy and breastfeeding?

Pregnancy Based on animal studies and its mechanism of action, Idhifa can cause harm to a fetus when taken during pregnancy. There are no adequate studies in humans to determine the specific risks, but the medication has shown embryo-fetal toxicity in animal research. Individuals who are pregnant or planning to become pregnant should discuss the potential risks and benefits with their healthcare provider. Contraception Healthcare providers typically recommend the following for patients of reproductive potential: Females: Use effective contraception during treatment and for at least one month after the final dose. Males: Use effective contraception (such as condoms) during treatment and for at least one month after the final dose if their partner is of reproductive potential. Breastfeeding It is currently unknown whether Idhifa passes into human breast milk or how it might affect a nursing infant. Because of the potential for serious side effects in a breastfed child, it is generally advised not to breastfeed during treatment and for at least one month after the last dose.

Q: What forms and strengths does Idhifa come in?

Dosage Forms Idhifa is supplied as a film-coated tablet intended for oral use. It is typically taken once daily. The tablets should be swallowed whole. Do not chew, crush, or split the tablets before swallowing.

Q: What is the FDA approval status of Idhifa?

FDA Approval History The U.S. Food and Drug Administration (FDA) approved Idhifa in August 2017. It was the first oral targeted therapy approved for adult patients with relapsed or refractory acute myeloid leukemia who have a specific genetic mutation known as isocitrate dehydrogenase-2 (IDH2). The drug was approved alongside a companion diagnostic test, the RealTime IDH2 Assay, which is used to identify patients who carry this specific mutation. Boxed Warning The prescribing information for Idhifa includes a Boxed Warning, the FDA's most serious warning, regarding the risk of differentiation syndrome. This condition is a serious and potentially fatal complication that occurs when leukemia cells mature too quickly. Symptoms of differentiation syndrome may include: Fever Cough or difficulty breathing Rapid weight gain Swelling in the arms or legs Fluid buildup around the lungs or heart Regulatory Safety Communications In 2018, the FDA issued a safety communication to alert healthcare professionals and patients that symptoms of differentiation syndrome were not always being recognized. The agency emphasized that if this condition is suspected, patients should be treated immediately with high-dose corticosteroids and monitored closely until their symptoms resolve. The FDA also updated the drug's prescribing information to include more detailed instructions on managing this risk.

Question 1

What is Idhifa?

Accepted Answer

Idhifa is a prescription medicine classified as an isocitrate dehydrogenase-2 (IDH2) inhibitor. It functions as a targeted therapy by blocking the activity of a specific enzyme that can contribute to the growth of abnormal cells.

By inhibiting this enzyme, the medication helps promote the maturation of blood cells. This mechanism is designed to restore more normal cell development within the body.

Question 2

What is Idhifa used for?

Accepted Answer

Idhifa is used to treat acute myeloid leukemia with IDH2 mutation.

Question 3

How does Idhifa work?

Accepted Answer

Targeting the IDH2 Mutation

Idhifa is designed for people with acute myeloid leukemia (AML) who have a specific genetic mutation in the isocitrate dehydrogenase-2 (IDH2) enzyme. In a healthy body, this enzyme helps cells produce energy. However, when the enzyme is mutated, it causes the body to produce too much of a substance called 2-hydroxyglutarate (2-HG).

Restoring Cell Maturity

High levels of 2-HG interfere with the normal development of blood cells. Instead of maturing into functional white blood cells that fight infection, the cells remain in an immature state known as blasts. These blasts multiply quickly and crowd out healthy blood cells in the bone marrow and blood.

Idhifa works by:

Blocking the mutated enzyme: The medication attaches to the mutated IDH2 enzyme to stop it from working.
Reducing 2-HG levels: By blocking the enzyme, Idhifa lowers the amount of 2-HG in the body.
Promoting differentiation: Once 2-HG levels drop, the immature leukemia cells are able to go through a process called differentiation, where they mature into normal, working blood cells.

Because Idhifa helps cells mature rather than simply killing them immediately, it is considered a type of differentiation therapy.

Question 4

What are the active ingredients in Idhifa?

Accepted Answer

The active ingredient in Idhifa is enasidenib.

Question 5

What are the side effects of Idhifa?

Accepted Answer

Common side effects of Idhifa may include:

Nausea
Diarrhea
Fatigue
and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Idhifa?

Accepted Answer

Idhifa belongs to the IDH2 inhibitor drug class.

Question 7

What is the dosage of Idhifa and how do I take it?

Accepted Answer

How to Take Idhifa

Idhifa comes as a tablet to be taken by mouth. It is usually taken once a day at approximately the same time. You may take this medication with or without food.

When taking Idhifa, follow these instructions:

Swallow the tablet whole.
Do not crush, chew, or break the tablet before swallowing.

Missed Doses

If you miss a dose of Idhifa, or if you vomit after taking a dose, take the missed dose as soon as you remember on the same day. If it is already the next day, skip the missed dose and take your next scheduled dose at the regular time. Do not take two doses at the same time to make up for a missed or vomited dose.

Question 8

Is Idhifa safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Based on animal studies and its mechanism of action, Idhifa can cause harm to a fetus when taken during pregnancy. There are no adequate studies in humans to determine the specific risks, but the medication has shown embryo-fetal toxicity in animal research. Individuals who are pregnant or planning to become pregnant should discuss the potential risks and benefits with their healthcare provider.

Contraception

Healthcare providers typically recommend the following for patients of reproductive potential:

Females: Use effective contraception during treatment and for at least one month after the final dose.
Males: Use effective contraception (such as condoms) during treatment and for at least one month after the final dose if their partner is of reproductive potential.

Breastfeeding

It is currently unknown whether Idhifa passes into human breast milk or how it might affect a nursing infant. Because of the potential for serious side effects in a breastfed child, it is generally advised not to breastfeed during treatment and for at least one month after the last dose.

Question 9

What forms and strengths does Idhifa come in?

Accepted Answer

Dosage Forms

Idhifa is supplied as a film-coated tablet intended for oral use. It is typically taken once daily.

The tablets should be swallowed whole. Do not chew, crush, or split the tablets before swallowing.

Question 10

What is the FDA approval status of Idhifa?

Accepted Answer

FDA Approval History

The U.S. Food and Drug Administration (FDA) approved Idhifa in August 2017. It was the first oral targeted therapy approved for adult patients with relapsed or refractory acute myeloid leukemia who have a specific genetic mutation known as isocitrate dehydrogenase-2 (IDH2). The drug was approved alongside a companion diagnostic test, the RealTime IDH2 Assay, which is used to identify patients who carry this specific mutation.

Boxed Warning

The prescribing information for Idhifa includes a Boxed Warning, the FDA's most serious warning, regarding the risk of differentiation syndrome. This condition is a serious and potentially fatal complication that occurs when leukemia cells mature too quickly. Symptoms of differentiation syndrome may include:

Fever
Cough or difficulty breathing
Rapid weight gain
Swelling in the arms or legs
Fluid buildup around the lungs or heart

Regulatory Safety Communications

In 2018, the FDA issued a safety communication to alert healthcare professionals and patients that symptoms of differentiation syndrome were not always being recognized. The agency emphasized that if this condition is suspected, patients should be treated immediately with high-dose corticosteroids and monitored closely until their symptoms resolve. The FDA also updated the drug's prescribing information to include more detailed instructions on managing this risk.

Question 11

What should I know about Idhifa and cost?

Accepted Answer

Factors Influencing Cost

The total cost of Idhifa can vary based on your treatment plan, insurance coverage, and the pharmacy you use. Because Idhifa is a brand-name medication without a generic equivalent, the price is generally higher than older or off-patent treatments.

Insurance Coverage

Most insurance providers require prior authorization for Idhifa. This means your doctor must submit a request to your insurance company to confirm that the drug is medically necessary before the insurer will agree to cover the cost. Your out-of-pocket expenses, such as deductibles and co-pays, will depend on your specific plan.

Specialty Pharmacies

Idhifa is often distributed through specialty pharmacies. These pharmacies focus on medications for complex conditions like leukemia and may offer specialized services to help you manage your prescription and understand your insurance benefits.

Financial Assistance

Patients who have difficulty affording Idhifa may be eligible for support programs. These can include manufacturer-sponsored assistance for those with commercial insurance or programs for individuals who are uninsured. Additionally, some independent foundations provide grants to help cover the costs of cancer medications.

Idhifa

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Idhifa

Hospitals.net Disclosure